Cryopreserved valved homograft conduit for the treatment of complex congenital heart disease in 17 cases

Wu Zhong,Shi Min-ke,Shao Jun,Wang Qiang,Chen Bao-jun,Cao Bin,Wang Dong-jin
DOI: https://doi.org/10.3321/j.issn:1673-8225.2008.18.041
2008-01-01
Abstract:AIM:Valved homograft conduit is frequently used to treat complex congenital heart disease and shows a satisfactory short and moderate-term effect, but its long-term effect still needs to improve. This study evaluated the clinical outcome of cryopreserved self-designed valved homograft conduit in the treatment of complex congenital heart disease. METHODS:Seventeen patients with complex congenital heart disease underwent valved homograft conduit transplantation in Department of Thoracic and Cardiovascular Surgery, Drum Tower Hospital of Medical College of Nanjing University between January 2003 and October 2007. There were 7 cases with Tetralogy of Fallot, 3 cases with pulmonary atresia complicated by ventricular septal defect, 2 cases with congenital aortic valve stenosis, 2 cases with double outlet right ventricle complicated by pulmonary stenosis, and 3 cases with transposition of the great arteries complicated by with ventricular septal defect and pulmonary stenosis including 1 case complicated with double outlet right ventricle. Homologous transannular graft with valve was used in 7 cases;Rastelli operation was performed on 4 cases;right ventricular and pulmonary artery homograft on 3, ROSS procedure on 2 and total vena cava pulmonary artery connection on 1. Treatment outcome was observed early after operation and during follow-up. RESULTS:Of 17 patients, 16 completed the surgery, and 1 died of extracorporeal circulation after heart resuscitation during the surgery. One case died of low cardiac output syndrome and heart failure after surgery. The other 15 cases recovered and discharged from hospital. During the follow-up for 1-48 months, the life quality of 15 patients was good. Echocardiography showed no obvious calcification or degeneration was found in the implanted valved homograft conduits. CONCLUSION:Cryopreserved valved homograft conduit has good early and midterm effects in the treatment of complex congenital heart disease. The prevention of valved homograft conduit calcification and degeneration is significant for further clinical study.
What problem does this paper attempt to address?